| Code | CSB-RA003995MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to eculizumab, targeting the complement component 5 (C5) protein. C5 plays a critical role in the complement cascade, a key component of the innate immune system. Upon activation, C5 is cleaved into C5a, a potent anaphylatoxin that promotes inflammation, and C5b, which initiates formation of the membrane attack complex (MAC) that lyses target cells. Dysregulated complement activation through C5 is implicated in various pathological conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated disorders.
Eculizumab, the reference antibody, is a humanized IgG2/4κ monoclonal antibody that binds to C5 and prevents its cleavage, thereby inhibiting both the generation of C5a and formation of the MAC. This biosimilar provides researchers with a valuable tool for investigating complement-mediated pathophysiology, exploring therapeutic mechanisms in complement-related diseases, and conducting preclinical studies of complement inhibition. It serves as an important reagent for understanding C5 biology and evaluating complement system involvement in inflammatory and autoimmune conditions.
There are currently no reviews for this product.